Home » Posts tagged 'dialight'

Tag Archives: dialight

Ian Pollard – Ibstock Warns As Production Falls

Ibstock plc IBST updates that demand in the UK brick markets is robust and factories have been producing at, or close to, full capacity for an extended period. Adjusted EBITDA for the six months to the 30th June  is expected to be about £58m  which reflects the impact of bad weather at the start of the year and higher energy costs.But whilst demand from the new housing sector has been strong and market fundamentals are favourable, there are clouds on the horizon and it looks as if the tide may be turning to reflect the realities of life among the house builders. In recent months and particularly in July, production has been lower than expected and it is now anticipated that output for the second half of the year, will be below expectations.

Keller Group KLR is increasing its interim dividend by 24% for the half year to the 30th June, after rises in statutory pofit before tax and earnings per share of 31% and 37% respectively.   First half revenue was a record at £1,075m with constant currency growth of 15%. The strong financial performance was achieved despite a harsh winter in the northern hemisphere and markets have remained broadly healthy.

Cranswick CWK revenue in the first quarter to the 30th June was 3.2% ahead of the same period last year and export revenues were modestly ahead. The Group is in a robust financial position with net debt of 18m. a year ago having been turned into net cash of 8m. at the quarter end despite substantial ongoing capital investment.

Senior plc SNR Trading in the six months to the 30th June has been slightly ahead of expectations with profit before tax for the half year riing by 36% and basic earnings per share by 25%. The interim dividend is to be increased by 6.8% and he order book remains strong across most of the businesses.

Dialight plc DIA claims to have taken targeted actions to improve its operational performance during the six months to the 30th June. Despite that, statutory profit before tax fell from 4.0m. to 2.8m. and earnings per share  from 8p to 6.4p.  Late orders have been significantly reduced since the start of the year and on-time delivery and cost performance are now both excellent, it says. The move from recovery to growth leaves the Group excited by its future prospects.

Beachfront villas & houses for sale in Greece;   http://www.hiddengreece.net

Dialight Descends Into Gloom

There is a mystery about the  2015 results for Dialight (DIA) in that revenue rose slightly from £159.8m to £161.4m whilst everything else nosedived and no real explanation is being given for a disaster which affects both shareholders and employees.

The best that the company can, or will say, is that the year to 31st December was a difficult one because of operating challenges which it does not bother to specify but which it claims were exacerbated by downturns across a number of its markets.

The result is devastating for shareholders and employees.  No final dividend is being paid. Even worse the company is closing its UK manufacturing plant after 40 years, with all UK staff at risk of redundancy, except of course for the directors who are allowing themselves to continue to preside over the fiasco, save for two board members whose heads are to roll. Manufacturing will be transferred to a global manufacturing partner whose location and identity the board thinks should be kept a closely guarded secret.

Now for the statistics. Underlying operating profit plunged by 66% and a strategic review imposed additional costs of £9m. Statutory earnings per share were transformed  from 29.4p to a loss of 6.4p. whilst another major transformation saw statutory profit fall from £15.5m to a loss of £3.9m and net cash of £0.6m., become debt of £3.8m. Underlying operating margins declined from 11% to 4%

At least the board  tried a new strategy during the year with a new 3 year plan but remains silent on whether that was alleviated the problems or added to them. What the board does say is that it only has confidence in the medium to long term outlook which indicates that the short term outlook could be fairly grim.

Another mystery is the company’s October trading update which made it fairly clear that the third quarter had not been good but gave no cause for concern  about quarter 4 which by then had of course, already started. In fact the shares which had halved to 400p in the year to February 2016, had since rallied strongly  to 516p at yesterdays close. This morning they have, so far, shed over 5% to 488p.

They had peaked in September 2013 at 1402p, before starting their long decline which now seems likely to continue further.

One can only wonder who, if anyone, will shed light on, or even accept a modicum of responsibility for what is a very sad and disturbing story.

Villas & houses for sale in Greece;   http://www.hiddengreece.net

 

 

Daily Actions – UK Main & AIM markets 27012016

IntellisysLogoDaily Actions is a daily summary analysis of changes in short term actions from our Daily Recs – AIM and Daily Recs Main markets reports. This report is typically distributed before the open of trading in London.

AIM Market

ST Rec. changed
From To
Basic Resources
Amur Minerals Corporation Buy Neutral
Arian Silver Buy Neutral
Avocet Mining Neutral Sell
Financial Services
ADVFN Buy Strong Buy
Amphion Innovations Neutral Buy
Health Care
Abcam Sell Neutral
AorTech International Neutral Buy
Taihua Buy Neutral
Media
Mediazest Buy Neutral
Oil & Gas – Producers
Baron Oil Buy Neutral
Plexus Holdings Buy Strong Buy
Technology
Indigovision Group Neutral Buy

 

Main Market

ST Rec. changed
From To
Banks
Lloyds Banking Group Buy Neutral
Electronics & Electrical Equipment
Dialight Neutral Buy
Engineering & Machinery
IMI Buy Neutral
Food & Drugs Stores
Tesco Neutral Sell
Food Producers & Processors
Cranswick Sell Neutral
Unilever (UK) Sell Neutral
Information Technology & Hardware
Filtronic Sell Neutral
Leisure & Hotels
Millennium & Copthorn Hotels Buy Neutral
Personal Care & Household Products
PZ Cussons Neutral Buy
Pharmaceuticals & Biotechnology
AstraZeneca Sell Neutral
Real Estate – REIT
Primary Health Properties Sell Neutral
Real Estate – REIS
CLS Holdings Neutral Buy
Support Services
Aggreko Buy Neutral

 

RISK WARNING

Intellisys Intelligent Analysis Limited (‘Intellisys’) does not make personal recommendations. The information in this publication is provided solely to enable you to make your own investment decisions. If you are unsure about dealing in shares and other equity investments, you must contact your financial adviser as these types of investments may not be suitable for everyone. The value of stocks and shares, and the income from them, can fall as well as rise and you may not get back the full amount you originally invested. If denominated in a foreign currency, fluctuations in the exchange rate will also affect the value of stocks and shares and the income from them. Past performance is not necessarily a guide to future performance. You agree to abide fully with Intellisys’ Term & Conditions, which are available to www.intellisys.uk.com

 

The full reports are available from Intellisys Intelligent Analysis website (www.intellisys.uk.com) by clicking on the ‘Research’ tab.

 

DISCLAIMER: Intellisys Intelligent Analysis Limited has prepared this report. Intellisys (“Intellisys”) is the trading name of Intellisys Intelligent Analysis Limited. Intellisys Intelligent Analysis Limited is a provider of financial research reports that indicate the possible value of quoted company shares. The information contained within any and all of Intellisys’ reports are designed to present an objective assessment of the possible value or relative value of a company and/or an actuarial sector or stock market index. Intellisys utilises as extensive as possible range of valuation tools and proprietary systems to derive its outputs. The base data for the models are derived from sources believed to be accurate but Intellisys Intelligent Analysis Limited does not warrant or guarantee the accuracy or reliability of the source data or its models and proprietary systems. Subscribers, and casual readers, should not rely upon the Intellisys’ research outputs when forming specific investment decisions but should seek advice specific to their situation and investment requirements from a person authorised under the Financial Services and Markets Act 2000, before entering into any investment agreement.Intellisys Intelligent Analysis Limited has used reasonable care and skill in compiling the content of this report. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness or accuracy of the information and no responsibility or liability is accepted to the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. In no event will Intellisys Intelligent Analysis Limited, Intellisys or any of its officers, employees or agents be liable to any other party for any direct, indirect, special or other consequential damages arising from the use of this report.

The Intellisys Intelligent Analysis Limited and/or Intellisys reports are not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the publication or availability of the Intellisys Intelligent Analysis Limited and/or Intellisys information may be prohibited. Persons in respect of whom such prohibitions apply must not access the Intellisys Intelligent Analysis Limited and/or Intellisys reports. Neither this document, nor any copy in whatever form of media, may be taken or transmitted into the United States, Canada, Australia, Ireland, South Africa or Japan or into any jurisdiction where it would be unlawful to do so. Any failure to comply with this restriction may constitute a violation of relevant local securities laws. Recipients of Intellisys Intelligent Analysis Limited and/or Intellisys reports outside the UK are not covered by the rules and regulations made for the protection of investors in the UK.

Any user distributing information taken from any Intellisys Intelligent Analysis Limited or Intellisys report and/or the Intellisys website, in whatever form, to any other person, agrees to attach a copy of this Disclaimer and the Terms and Conditions of Use pages and obtain the agreement of such other person to comply with the terms set forth.

Intellisys’ published reports are published for information purposes and only available to market counterparties, high net-worth and sophisticated individual investors.

No Intellisys report constitutes an offer or invitation to trade, sell, purchase or acquire any shares or other financial instruments in any company or any interest therein, nor shall it form the basis of any contract entered into for the sale of shares or any other financial instrument in any company.

Intellisys Intelligent Analysis Limited believes that the information within each and any of its reports to be correct, but its accuracy or completeness cannot be guaranteed. No representation or warranty, expressed or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or mis-statements, negligent or otherwise.

Intellisys Intelligent Analysis Limited (including its Directors, employees and representatives) or a connected person may have positions in or options or other financial instruments on any of the securities mentioned within a report, and may buy, sell or offer to purchase or sell such securities from time to time, subject to restrictions imposed by internal rules.

Subscribers, and casual reader, are reminded that the value of any financial instrument may go up or down and that past performance is not necessarily a guide to future performance.

Intellisys Intelligent Analysis Limited is not registered with or regulated by any financial regulatory authority and does not offer, provide or purport to provide or offer investment advice. Intellisys Intelligent Analysis Limited can be contacted at Woodfield Cottage, The Street, Mortimer, Berkshire, United Kingdom RG7 3DW.

 

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.